Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Completed 32Withdrawn 4Unknown 2Recruiting 2Active not recruiting 2Terminated 1Suspended 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Melanoma 4Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma 2Waldenstrom Macroglobulinemia 1Solid Tumor 1Skin Neoplasms 1Sezary Syndrome 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Intraocular Lymphoma 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1

Interventions

Nivolumab 17Ipilimumab 14pembrolizumab 11Cyclophosphamide 8trametinib 7dabrafenib 6Interleukin-2 6aldesleukin 5Vemurafenib 5Radiotherapy 5sargramostim 4130-nm albumin-bound paclitaxel 4fludarabine 3encorafenib 3binimetinib 3Specimen Handling 3Radiosurgery 3Melphalan 3Granulocyte-Macrophage Colony-Stimulating Factor 3fludarabine phosphate 2Magnetic Resonance Spectroscopy 2Introns 2Infliximab 2Celecoxib 2CTLA-4 Antigen 2Biopsy 2Bevacizumab 2Albumin-Bound Paclitaxel 2yeast-CEA vaccine 1vitespin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × Melanoma × sargramostim × Clear all
NCT04703426 2023-05-22

Sargramostim (GM-CSF) + PD-1

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Dermatologic

Melanoma

NCT01826864 2020-07-27

Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

Jonsson Comprehensive Cancer Center

Phase 3 Withdrawn
Dermatologic

Melanoma

NCT03282188 2018-05-04

REO13 Melanoma With of Without GM-CSF

University of Leeds

Phase 1/2 Withdrawn
Dermatologic

Melanoma, Skin Neoplasms

NCT00085579 2012-12-12

Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Memorial Sloan Kettering Cancer Center

Phase 2 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡